Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost
- 1 January 2003
- journal article
- Published by Microbiology Society in Journal of General Virology
- Vol. 84 (1) , 203-213
- https://doi.org/10.1099/vir.0.18589-0
Abstract
Eight monoclonal antibodies (MAbs) prepared against the flaviviruses Saint Louis encephalitis, dengue 2 and dengue 3 viruses all recognized epitopes on the envelope protein of the prototype flavivirus, yellow fever (YF) virus. Three of these MAbs with flavivirus group-common specificity and two MAbs with a flavivirus-subgroup specificity were found to distinguish wild-type YF viruses from YF 17D-204 vaccine virus, but not from the closely related 17DD vaccine virus, nor from the French neurotropic vaccine virus. This pattern of reactivity was seen only with viruses grown in Aedes albopictus C6/36 cells and not with viruses grown in vertebrate cells (SW13 and Vero cells), where all five MAbs recognized epitopes on both wild-type and 17D-204 viruses. Examination of adult A. aegypti mosquitoes infected with the same YF viruses as above gave a different pattern of results to those in C6/36 cells. Thus, epitope expression differs between mammalian and arthropod cells and between arthropod cells in vitro and in vivo. Neutralization tests showed that all five MAbs would neutralize wild-type Asibi virus grown in SW13 cells, but not Asibi virus grown in C6/36 cells, nor 17D-204 vaccine virus grown in either cell type. Therefore, it is concluded that when YF virus is grown in mosquito cells, wild-type virus is antigenically and biologically distinct from the 17D-204 vaccine virus.Keywords
This publication has 78 references indexed in Scilit:
- Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South AfricaJournal of Virology, 2002
- Immunization with Recombinant Canarypox Vectors Expressing Membrane-Anchored Glycoprotein 120 Followed by Glycoprotein 160 Boosting Fails to Generate Antibodies That Neutralize R5 Primary Isolates of Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 2000
- Construction, Biological Activity, and Immunogenicity of Synthetic Envelope DNA Vaccines Based on a Primary, CCR5-Tropic, Early HIV Type 1 Isolate (BX08) with Human CodonsAIDS Research and Human Retroviruses, 2000
- Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Cytokine-Augmented DNA VaccinationScience, 2000
- Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost RegimenThe Journal of Immunology, 2000
- Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in miceJournal of General Virology, 1999
- Looking forward to the back of HIVNature Medicine, 1998
- Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.Journal of General Virology, 1998
- Core Structure of gp41 from the HIV Envelope GlycoproteinPublished by Elsevier ,1997
- Efficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal AntibodyScience, 1994